Clinical Trials Browser

Phase 1/2 × Has results × repotrectinib × Clear all

NCT05071183 2024-04-02

A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors

Phase 1/2 Terminated

9 enrolled 17 charts

Neoplasm Metastasis